An interview with Cynata Vice President of Product Development Dr Kilian Kelly provides details on the important implications of Cynata’s recent successful clinical trial in graft-versus-host disease (GvHD).
Dr Killian Kelly, Cynata’s Vice President of Product Development spoke to Proactive Investors at the recent ASX Small and Mid-Cap Conference in Sydney.
Dr Ross Macdonald is interviewed by Nadine Blayney of Sky News Business - Tech.Biz
You can watch the full interview on the link below, starting at timecode: 10:10s
Read the special report published in “Stockhead”, a journalistic news service dedicated to covering the stories of emerging, ASX-listed companies
Cynata is pleased to inform investors that, following the engagement of Japan- based investor relations firm Finantec Co., Ltd. (as announced on the 9th of August 2017), a series of investor briefings will be conducted in Japan this week to further raise awareness among the Japanese investor community.